Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Sever-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay

Documenti analoghi

• Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Sever-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay
  di: Shieh-Yueh Yang, et al.
  Pubblicazione: (2026-06-01)
• Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline
  di: Shieh-Yueh Yang, et al.
  Pubblicazione: (2020-10-01)
• Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
  di: Huei-Chun Liu, et al.
  Pubblicazione: (2020-03-01)
• Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays
  di: Ming-Jang Chiu, et al.
  Pubblicazione: (2019-02-01)
• Microarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex.
  di: Valentina Gatta, et al.
  Pubblicazione: (2011-01-01)